- Home
- BUD vs SNY Comparison
BUD vs SNY Comparison
Compare BUD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- SNY
- Stock Information
- Founded
- BUD 1366
- SNY 1994
- Country
- BUD Belgium
- SNY France
- Employees
- BUD N/A
- SNY N/A
- Industry
- BUD Beverages (Production/Distribution)
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- BUD Consumer Staples
- SNY Health Care
- Exchange
- BUD Nasdaq
- SNY Nasdaq
- Market Cap
- BUD 136.0B
- SNY 116.5B
- IPO Year
- BUD N/A
- SNY N/A
- Fundamental
- Price
- BUD $61.78
- SNY $47.11
- Analyst Decision
- BUD Strong Buy
- SNY Hold
- Analyst Count
- BUD 4
- SNY 1
- Target Price
- BUD $72.00
- SNY $65.00
- AVG Volume (30 Days)
- BUD 2.7M
- SNY 2.3M
- Earning Date
- BUD 07-31-2025
- SNY 07-31-2025
- Dividend Yield
- BUD 1.38%
- SNY 3.37%
- EPS Growth
- BUD 21.01
- SNY 118.56
- EPS
- BUD 3.50
- SNY 8.65
- Revenue
- BUD $58,520,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- BUD $2.37
- SNY $2.85
- Revenue Next Year
- BUD $5.40
- SNY $6.65
- P/E Ratio
- BUD $17.54
- SNY $5.49
- Revenue Growth
- BUD N/A
- SNY 15.65
- 52 Week Low
- BUD $45.94
- SNY $44.73
- 52 Week High
- BUD $72.13
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- BUD 38.38
- SNY 43.53
- Support Level
- BUD $56.97
- SNY $46.14
- Resistance Level
- BUD $67.11
- SNY $47.54
- Average True Range (ATR)
- BUD 0.95
- SNY 0.81
- MACD
- BUD -0.50
- SNY -0.17
- Stochastic Oscillator
- BUD 33.04
- SNY 38.54
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.